Skip to main content
European Commission logo
English English
CORDIS - EU research results
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Modular cell factories for the production of 100 compounds from the shikimate pathway

Project description

Producing 100 high added value compounds from the shikimate pathway

Chemical synthesis is often difficult and usually results in undesired by-products. While nature can provide many products, their very low concentrations make extraction costly. Conversely, microbial production is a well-established process for compounds that are host-produced or have fully characterised biosynthetic pathways. However, major screenings are required for the efficient production of target compounds derived from nature in industrial applications. With this in mind, the EU-funded SHIKIFACTORY100 project aims to produce over 100 high added value compounds from the shikimate pathway, a hub in cell metabolism, by developing an optimised shikimate chassis. It will also propose and implement novel biosynthetic routes exploring enzyme promiscuity so as to recommend new pathways for the production of known and newly-designed compounds.

Objective

Chemical synthesis is often difficult and may be subject to unclear mechanisms, frequently producing undesired by-products, while the complexity of some compounds may rendered them virtually unattainable. Nature can provide a wealth of products, however typically at very low concentrations, which makes their extraction process expensive. Conversely, microbial production is a well-established process for compounds naturally produced by the hosts or for which there are fully characterised biosynthetic pathways. However, relying on nature’s diversity as a provider for industrial applications typically requires major screenings for pathways, genes and optimisation of cell factories for the efficient production of the target compounds.
SHIKIFACTORY100 project aims towards the production of a universe of more than 100 high-added value compounds from the shikimate pathway, a hub in cell metabolism, through the development of an optimised shikimate chassis) and the proposal and implementation of novel biosynthetic routes exploring enzyme promiscuity to propose new pathways for the production of known and newly designed compounds. To champion SHIKIFACTORY100 project a consortium with some of the most relevant players in Europe has been assembled, covering research leading institutions in computational design, rapid prototyping and in vivo implementation of pathways and cell factories. As such, six world-leading research partners, four biotechnology SMEs with complementary focus areas and one large industrial company have been integrated. The research partners will be responsible for novel methods for pathway discovery and compound design, collaborating with the SMEs in the implementation and optimisation of the chassis, while SMEs and industrial partners will lead the assessment of the products and the exploitation of the results for different application areas. The industrial partner will be responsible for the validation of the production.

Call for proposal

H2020-NMBP-TR-IND-2018-2020

See other projects for this call

Sub call

H2020-NMBP-BIO-2018-two-stage

Coordinator

SILICOLIFE LDA
Net EU contribution
€ 1 228 625,00
Address
RUA DO CANASTREIRO 15
4715 387 Braga
Portugal

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Continente Norte Cávado
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 1 228 625,00

Participants (12)